<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02119234</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-05993AA1-04</org_study_id>
    <secondary_id>2013-003770-27</secondary_id>
    <nct_id>NCT02119234</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients</brief_title>
  <acronym>TRIPLE 4</acronym>
  <official_title>Open-label, Randomized, 3-way Cross-over, Placebo Controlled, Single Dose Clinical Pharmacology Study in COPD Patients After Inhalation of CHF 5993 pMDI Using the Standard Actuator With or Without AeroChamber Plus Flow-Vu VHC Spacer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is performed to investigate the effect of the spacing device on the
      pharmacokinetics of CHF 5993 pMDI active ingredients administered with and without
      Aerochamber Plus Flow-vu antistatic VHC spacer as a single administration in COPD patients.
      Moreover, the general safety and tolerability of the treatments will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of B17MP, formoterol and glycopyrrolate</measure>
    <time_frame>Over 24 and 48h after single administration</time_frame>
    <description>AUCt (up to the last quantifiable concentration) and Cmax (maximum concentration) from plasma concentrations vs time profiles.
over 24h for formoterol and B17MP, over 48h for glycopyrrolate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other pharmacokinetic parameters for formoterol, glycopyrrolate and B17MP in plasma</measure>
    <time_frame>over 24 or 48h after single administration</time_frame>
    <description>B17MP AUC0-30min, AUC0-24h, AUCinf, tmax, half-life Formoterol AUC0-30min, AUC0-24h, AUCinf, tmax, half-life Glycopyrrolate AUC0-30min, AUC0-48h, AUCinf, tmax, half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>over a period of 6 to 11 weeks</time_frame>
    <description>from the signature of the informed consent until the follow-up phone call</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function</measure>
    <time_frame>30 min after single administration</time_frame>
    <description>FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma cortisol</measure>
    <time_frame>over 24 h after single administration</time_frame>
    <description>cortisol AUC0-24h, Cmin and tmin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cortisol urinary excretion</measure>
    <time_frame>over 24 h after single administration</time_frame>
    <description>cortisol excretion corrected and not corrected for creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>potassium plasma profile</measure>
    <time_frame>over 24 h after single administration</time_frame>
    <description>potassium AUC0-24h, tmin and Cmin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>over 24 h after single administration</time_frame>
    <description>systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG parameters</measure>
    <time_frame>over 24 h after single administration</time_frame>
    <description>extracted from holter recording HR, QTcF, PR and QRS</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>CHF5993 pMDI + Spacer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using Aerochamber Plus Flow-vu VHC spacer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF5993 pMDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using standard actuator only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pMDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pMDI x 4 inhalations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclometasone/formoterol/glycopyrrolate</intervention_name>
    <arm_group_label>CHF5993 pMDI + Spacer</arm_group_label>
    <arm_group_label>CHF5993 pMDI</arm_group_label>
    <other_name>CHF5993 pMDI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo pMDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD patients

          -  smokers or ex-smokers

          -  post-bronchodilator FEV1 between 30 and 60% of predicted value

        Exclusion Criteria:

          -  Positive serology to HIV and hepatitis

          -  Known respiratory disorder other than COPD

          -  Recent COPD exacerbations or hospitalization for COPD

          -  Treatment with non-permitted concomitant medication

          -  clinically relevant concomitant disease

          -  clinically relevant abnormal laboratory or ECG parameters
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Kuna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Lodz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University in Lodz</name>
      <address>
        <city>Lodz</city>
        <state>ul. Kopci≈Ñskiego 22</state>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2014</study_first_submitted>
  <study_first_submitted_qc>April 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>March 20, 2015</last_update_submitted>
  <last_update_submitted_qc>March 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

